These results indicate that UBE2L6 is prominently upregulated during leukemic cell differentiation rather than solely on ATRA treatment and that this effect is not restricted to APL cells carrying the PML‐RARα fusion oncoprotein. The gene discussed is PML; the disease is acute promyelocytic leukemia.